1.76
+1.73%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Optomed Oyj
Its shares trade on Nasdaq Helsinki under the ticker OPTOMED.HE. It has been listed since 9 December 2019. In the fiscal year to 31 December 2025, it reported revenue of €17.1m and a net loss of €6.6m. At that date it held total assets of €32.0m and shareholders' equity of €24.0m.
Optomed Oyj engages in the provision of handheld fundus cameras and eye-screening solutions. The company is headquartered in Oulu, Oulun. The company went IPO on 2019-12-09. The Group's Parent Company, Optomed Oyj, is responsible for, among other things, the management of the Group as well as finance and accounting functions, human resources, legal affairs and corporate communication. The Group's business is managed through two reportable segments: Devices and Software. The Devices segment develops, commercializes and manufactures easy-to-use and affordable handheld fundus cameras. The Software segment develops and sells screening software for diabetic retinopathy and cancer screening for healthcare organizations. The Optomed Group consists of the parent company Optomed Oyj and four subsidiaries in Finland, China, the USA and Hong Kong.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 9 Dec 2019
- Employees
- 116
- Website
- optomed.com ↗
Leadership
Pay as last reported
- Mr. Petri SalonenChairman of the Board, since 2006€121,000
- Mr. Juho HimbergChief Executive Officer, Member of the Leadership Team
- Mr. Sakari KnuuttiInterim Chief Financial Officer, Chief Legal Officer, Member of the Leadership Team, since 2022
- Mr. Markku MyllylaVice President - Software, Member of the Leadership Team
- Ms. Laura PiilaVice President - Devices, Member of the Leadership Team
- Mr. Xisi GuoDirector
- Mr. Sameer BadlaniIndependent Director
- Mr. Seppo MaekinenIndependent Director€18,000
- Mr. Reijo TauriainenIndependent Director€20,000
- Mr. Anna TenstamIndependent Director€18,000
- Dr. Leana WenIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Optomed Oyj's Devices segment develops handheld fundus cameras for eye screening.
- The Software segment provides diabetic retinopathy screening software for healthcare organizations.
- Optomed Oyj has four subsidiaries in Finland, China, the USA, and Hong Kong.
Weaknesses
- Optomed Oyj's IPO occurred in December 2019, limiting recent market exposure.
- The company employs only 116 full-time employees, indicating a small operational scale.
- Optomed Oyj's business is managed through two reportable segments, which may limit diversification.
Opportunities
- The Devices segment's handheld fundus cameras target the growing eye-screening market.
- The Software segment's diabetic retinopathy screening software can expand into new healthcare markets.
- Optomed Oyj's subsidiaries in China and the USA present opportunities for international growth.
Threats
- The Health Care sector faces regulatory challenges that could impact Optomed Oyj's operations.
- The company's reliance on two reportable segments may increase vulnerability to market shifts.
- Optomed Oyj's limited employee count of 116 may hinder rapid expansion or crisis response.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.